Compare RUN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | SRPT |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2015 | 2000 |
| Metric | RUN | SRPT |
|---|---|---|
| Price | $8.82 | $20.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 29 |
| Target Price | $18.80 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 8.3M | 2.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | 1.04 | ★ 2.99 |
| Revenue | $858,578,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $8.71 | ★ $7.22 |
| Revenue Growth | 12.97 | ★ 15.58 |
| 52 Week Low | $8.61 | $14.68 |
| 52 Week High | $22.44 | $25.32 |
| Indicator | RUN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 71.58 |
| Support Level | $8.61 | $20.12 |
| Resistance Level | $11.19 | $23.71 |
| Average True Range (ATR) | 0.44 | 1.10 |
| MACD | 0.02 | 0.37 |
| Stochastic Oscillator | 3.56 | 84.24 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.